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Background: Hypermethylation of tumor suppressor gene has been reported in various 
types of leukemia with potential involvement in the inactivation of regulatory cell cycle 
and apoptosis genes. 
Methods: To evaluate the methylation status at initial diagnosis and morphologic com-
plete remission (CR) period in childhood acute lymphoblastic leukemia (ALL), we ana-
lyzed the methylation status of three key genes (CDH1, p16 and DAPK) in 43 childhood 
ALL patients and 7 healthy bone marrow (BM) donors. 
Results: CDH1 was methylated in 26 (60.4%) patients, p16 in two (4.6%) patients and 
DAPK in six (13.9%) patients at the time of diagnosis. Twenty nine (67.4%) patients 
had methylation of at least one gene. None of the healthy BM donors showed methyl-
ation of the above genes. Age was the only factor which showed significant association 
with the presence of DNA methylation (P=0.03). None of the other clinicopathological 
factors showed association with initial methylation status. At the time of morphologic 
CR, all patients who had aberrant DNA methylation at the time of diagnosis had no 
detectable residual methylation. 
Conclusion: Since hypermethylation was found in around two thirds of pretreatment ALL 
patients and none in healthy BM donor, we suggest hypermethylation of some important 
genes is a biologic marker of childhood ALL. We recommend that further studies with 
a large number of patients should be conducted. 
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Introduction
Hypermethylation of DNA, which involves the addition 
of a methyl group to the carbon 5 position of the cytosine 
ring in a cytosine-guanine (CpG) pair, is known to be the 
most common and well-described epigenetic mechanism. 
CpG pairs are usually underrepresented in most of the 
mammalian genome. However, short regions rich in CpG 
content known as CpG islands are found in the proximal 
promoter regions of almost half of the genes in the human 
genome, and are generally unmethylated in normal cells 
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[1-3]. Methylation of these promoter-associated areas has 
been associated with gene silencing which serves as an al-
ternative mechanism by inactivating functionally relevant 
genes related to diverse human pathologies including can-
cer and aging [4,5]. In cancer, the aberrant hypermethylation 
of CpG islands surrounding gene promoter regions is the 
most well-investigated epigenetic change to occur in tumors. 
CpG island hypermethylation has been described in various 
types of human malignancies, and is associated with in-
appropriate transcriptional silencing of functionally important 
cancer related genes, including tumor-suppressor genes [6,7].
Hypermethylation of promoter-associated CpG islands al-
so has been found in acute lymphoblastic leukemia (ALL). 
Initial studies in ALL were targeted on the analysis of single 
genes such as calcitonin [8-10], p73 [11,12], p15 [13-15], 
E-cadherin (CDH1) [16], and so on. Further studies focusing 
upon hypermethylation of multiple genes have proved that 
concurrent methylation of multiple genes is a common fea-
ture in both adult and childhood ALL [17,18]. The studies 
in Philadelphia chromosome (Ph)-negative adult ALL and 
acute myeloid leukemia (AML) have shown that residual 
methylation at remission could predict poor prognosis, sug-
gesting that DNA methylation could be a potential bio-
marker in ALL [19,20]. Furthermore, many studies implicated 
that methylation pattern in childhood ALL patients at diag-
nosis were different from that of adults [21-24]. To study 
these issues, we examined methylation status of three key 
genes in leukemia, CDH1, p16 and DAPK, at the time of 
initial diagnosis and at the time of morphologic complete 
remission (CR). CDH1 is a member of membrane glycoprotein, 
its function as a tumor suppressor and its loss due to meth-
ylation enables disaggregation of cancer cells from one an-
other and increases their metastatic potential. p16 is a im-
portant member of cyclin dependent kinase inhibitor, regu-
lated by a feedback loop with Rb. DAPK is a Ca+2/Calmod-
ulin regulated serine/threonine kinase, associated with the 
cytoskeleton, and participates in a wide range of apoptotic 
pathways. 
We also aimed to investigate the correlation of methyl-
ation status with clinicopathological features. 
Materials and Methods
1) Patients and samples
We studied 43 patients (24 males, 19 females) who were 
diagnosed as de novo childhood ALL between January 2006 
and February 2010. Diagnosis was established according to 
the standard morphologic, cytochemical, and immunophe-
notypic criteria. All patients were risk stratified and treated 
with protocols based on recognized prognostic factors, in-
cluding cytogenetic analysis. Criteria for CR were defined 
as restoration of normal hematopoiesis with a blast cell 
fraction of less than 5% by light microscopic examination 
of the bone marrow (BM) [25] after 4 weeks of induction 
chemotherapy. The median age at the time of diagnosis was 
4.8 years (range, 0.9-17 years). Patients were grouped ac-
cording to the National Cancer Institute (NCI) risk classi-
fication criteria [26] for statistical analyses. Other clinical 
characteristics of the patients are described in Table 1. The 
median follow up period of the patients was 5.4 years 
(range, 4.1-7.8 years). Seven healthy individuals were in-
cluded in this study for comparison. All of them were BM 
donors for their siblings. The median age of the donors was 
8.2 years (range, 3.5-22 years). 
Study samples were obtained from BM aspirates from the 
above patients at the time of diagnosis (prior to chemo-
therapy) and at the time of morphologic CR (after 4 weeks 
of induction chemotherapy). Patients with sample from one 
of the time points were not included in this study. All 43 
patients included in this study had achieved CR after in-
duction chemotherapy. BM aspiration samples were also 
obtained from 7 healthy individuals who were BM donors 
for their siblings. Consent for sample collection was ob-
tained from all patients and healthy individuals following 
the institutional guidelines. This study was reviewed and 
approved by the Institutional Review Board. 
2) Methylation specific PCR (MSP)
To study methylation patterns at the time of initial diag-
nosis and CR in childhood ALL, we analyzed the methyl-
ation status of three key genes related to its pathogenesis, 
CDH1, p16 and DAPK, in 43 patients. Gene selection was 
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based on the previous methylation studies in ALL [17,21,27, 
28]; we selected the three genes that are known to be fre-
quently methylated in childhood ALL [18,29]. 
Mononuclear cells were isolated using Ficoll-Hypaque 
density gradient centrifugation, and genomic DNA was ex-
tracted with QIAmp DNA blood mini kit (QIAGEN, CA, 
USA) following procedures according to the manufacturer’s 
instructions. Genomic DNA was modified using the sodium 
bisulfate as previously described by Herman et al. [30]. One 
microgram of genomic DNA was treated with sodium bi-
sulfate to convert all unmethylated cytosine residues to ur-
acil using EZ DNA Methylation kit (Zymo Research, CA, 
USA) following the manufacturer’s instructions. Modified 
DNA was stored at −70oC until used. PCR was performed 
using specific primers for CDH1, p16 and DAPK genes in 
43 pairs of samples from the patients and 7 samples from 
healthy donor. Two hundred nanograms of sodium bi-
sulfate modified DNA was used as a template in PCR re-
action containing 25 pmoles of each primer, 200 M each 
dNTP, 1 U AmpliTaq Gold DNA polymerase with 10X PCR 
buffer and 25 mM MgCl2 solution (Applied Biosystems, CA, 
USA) in a final volume of 25 L. PCR conditions and pri-
mers specific for methylated and unmethylated genes were 
the same as those used in the literature by Gutierrez et al. 
[18]. After amplification, 10 L of the PCR product was sep-
arated on a 2% agarose gel containing ethidium bromide. 
For each MSP reaction, a CpGenone universal methylated 
DNA (Millipore, MA, USA) and commercial normal human 
genomic DNA [Human Genomic DNA: Female (Promega, 
MI, USA)] was used as controls for methylation and unme-
thylation. Distilled water was used as a negative control for 
PCR in each set of reaction. Specificity of each reaction was 
demonstrated when methylated gene consistently yielded a 
band from universally methylated DNA. 
3) Statistical analysis
For statistical purposes, patients were classified into two 
different groups: unmethylated (no methylated genes) and 
methylated (at least one methylated gene). Association of 
methylation status with patient characteristics were ana-
lyzed using  test or Fisher exact test. Overall survival (OS) 
was measured from the day of diagnosis until death from 
any cause and was censored only for patients known to 
be alive at last contact. Disease-free survival (DFS) was 
measured from the day that CR was established until either 
relapse or death without relapse, and it was censored only 
for patients who were alive without evidence of relapse at 
the last follow-up. Comparisons among the groups were 
performed by analysis of variance with SPSS ver. 12.0 for 
Windows (SPSS Inc., Chicago, IL, USA). Estimated 5-year 
disease free survival and overall survival were based on the 
Kaplan-Meier method, and differences were tested using 
the log-rank test. An effect was considered statistically sig-
nificant if the P-value was 0.05 or less. 
Results
1) Methylation pattern at initial diagnosis and CR
Among 43 patients, methylation frequency of each gene 
at the time of initial presentation was as follows: 60.4% 
(n=26) for CDH1, 4.6% (n=2) for p16, and 13.9% (n=6) for 
DAPK. 67.4% (n=29) of all patients had methylation of at 
least one gene, whereas 32.6% (n=14) of the patients had 
no methylation at all. Five (11.6%) patients had methylation 
of two genes. Methylation of CDH1 showed considerably 
high frequency of methylation as previously reported [18]. 
However, p16 and DAPK were rarely methylated in this 
study.
To evaluate the dynamics of DNA methylation changes 
as a result of therapy, we also analyzed the methylation 
status of the above three genes at the time of morphologic 
CR with the paired samples. All patients who showed meth-
ylation at the time of initial presentation (n=29) revealed 
clear absence of methylation of all three genes at the time 
of CR. One patient who did not have methylation at initial 
presentation revealed methylation of CDH1 gene at the 
time of CR. The patient was an eight year-old girl who ex-
perienced bone marrow and CNS relapse after six months, 
and finally died of disease progression. Except this one pa-
tient, neither residual methylation nor new methylation was 
detected at the time of CR in childhood ALL patients. 
2) Clinical characteristics and methylation profile
We studied the association between DNA methylation 
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Table 1. Clinical characteristics and methylation profile of the patients
Features
All patients CDH1 p16 DAPK Methylation Nonmethylation
N % N % N % N % N % N %
Gender Male 24 55.8 15 62.5 2 8.3 3 12.5 17 70.8 7 29.2 
Female 19 44.2 11 57.9 0 0 3 15.8 12 63.2 7 36.8 
Agea) ＜2  4 9.3  1 25.0 0 0 1 25.0  1 25.0 3 75.0 
2-10 31 72.1 18 58.0 2 6.5 3 9.7 21 67.7 10 32.3 
≥10  8 18.6  7 87.5 0 0 2 25.0  7 87.5 1 12.5 
WBC count ＜50 32 74.4 20 62.5 2 6.3 5 15.6 23 71.9 10 31.3 
 (×109/L) ≥50 11 25.6  6 54.5 0 0 1 9.1  6 54.5 4 36.4 
NCI risk group SR 22 51.2 12 54.5 2 9.1 1 4.5 14 63.6 8 36.4 
HR 21 48.8 14 66.7 0 0 5 23.8 15 71.4 6 28.6 
Cytogenetic/molecular TEL-AML1, t(12;21) 11 25.6  8 72.7 1 7 0 0  8 72.7 3 27.3 
  abnormalities E2A-PBX1, t(1;19)  2 4.7  2 100 0 0 2 100  2 100 0 0 
mBCR-ABL, t(9;22)  4 9.3  2 50.0 0 0 0 0  2 50.0 2 50.0 
Hyperdiploidy  9 20.9  7 77.8 0 0 0 0  6 66.7 3 33.3 
State of Disease
  Complete remission 31 72.0 17 54.8 2 6.5 3  9.7 22 71.0 10 32.3 
  Relapse 12 27.9  6 50.0 0 0 1  8.3  3  25.0  1   8.3
  Death 15 34.9  7 46.7 0 0 2 13.3  4  26.7  3 20.0
Total patients 43 100 26 60.4 2 4.6 6 13.9 29 67.4 14 32.6 
Methylation, patients with DNA methylation of at least one gene; nonmethylation, patients with no methylation at all; WBC, white 
blood cell; NCI, National Cancer Institute; SR, standard risk; HR, high risk. 
a)P=0.03 (differences were tested using the log-rank test).
status and clinicopathological characteristics, including age, 
gender, initial WBC count, pretreatment cytogenetic analy-
sis and NCI risk group. Methylation profiles of the patients 
at initial presentation according to various clinicopatho-
logical characteristics are summarized in Table 1. 
Methylation of CDH1 was observed in 62.5% (15/24) of 
the male patients and 57.9% (11/19) of the female patients. 
By age, methylation of CDH1 was shown in 25.0% (1/4) 
of patients younger than two years of age, 58.0% (18/31) 
of patients between two and 10 years, and 87.5% (7/8) of 
patients older than 10 years.
Methylation of CDH1 gene was also found in 62.5% 
(20/32) of patients whose initial WBC counts were less than 
50,000/μL and in 54.5% (6/11) of those with more than 
50,000/μL of WBCs. The same gene was methylated in 
54.5% (12/22) of patients with standard risk and 66.7% 
(14/21) of patients with high risk. Frequencies of CDH1 
methylation in patients who had cytogenetic abnormalities 
were as follows: 72.71% (8/11) for TEL-AML1 positive pa-
tients, 50.0% (2/4) for minor BCR-ABL positive patients, 
and 100% (2/2) for E2A-PBX1 positive patients. 
Methylation of p16 was rarely found; only two out of 43 
patients showed methylation. Both two patients were male, 
aged between 2-10 years, and had standard risk. Methylation 
of DAPK was found in 12.5% (3/24) of males and 15.8% 
(3/19) of females. Methylation was observed in 25.0% (1/4) 
of patients under age of two, 9.7% (3/31) of patients be-
tween two and ten years old, and 25.0% (2/8) of patients 
older than 10 years Five out of six patients who had meth-
ylation of DAPK showed initial WBC count lower than 
50,000/μL. A majority of patients (5/6) with DAPK methyl-
ation were high risk group patients. 
Only age factor was significantly associated with the 
presence of methylation (P=0.03). Methylation was observed 
in 25.0% (1/4) of patients under age of two, whereas 12.5% 
(1/8) of patients older than 10 years showed nonmethylation. 
Since methylation of CDH1 accounted for a large majority 
of aberrant methylation of the studied genes, while only 
few or several cases had methylation of p16 and DAPK, 
CDH1 methylation predominantly contributed to the above 
results. Factors such as gender, initial WBC count, cytoge-
netic abnormalities, and NCI risk group did not show any 
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significant association with methylation status.
Since all patients who had methylation at the time of ini-
tial diagnosis showed clear absence of methylation at the 
time of CR, methylation profile at the time of CR was not 
available.
Estimated 5-year OS of all patients was 80.4% for stand-
ard risk patients and 65.6% for those with high risk. 
Estimated 5-year OS for methylated patients was 77.3% and 
83.2% for nonmethylated ones. Five year DFS for methy-
lated patients was 75.5% and 81.8% for the nonmethylated 
group. There was no statistical significance for OS and DFS 
between methylated and nonmethylated patients. 
Discussion 
There has been much evidence that DNA methylation 
plays a key role in cancer development [6,31]. An explosive 
amount of data has indicated the importance of epigenetic 
processes, especially those resulting in the silencing of key 
regulatory genes in all stages of cancer development [32]. 
In ALL, study of epigenetic alterations was a relatively ob-
scure field of research before; however, it has shown a 
considerable progress in the last decade. Studies on methyl-
ation of multiple genes in both adults and child patients 
have shown that multiple promoter CpG islands are com-
mon features in both groups [17,18,29,33]. However, differ-
ence in the patterns of methylation between pediatric and 
adult ALL has been suggested in several studies. While the 
report of Garcia-Manero et al. [33] indicated that there were 
no obvious differences in terms of the frequency of methyl-
ation observed in childhood and adult ALL, another study 
showed that epigenetic inactivation of p73/p15/p57 which 
was observed in close to 25% of adult patients was ex-
tremely rare in the younger patients [21]. Nakamura et al. 
[22] reported that methylation of p16, a rare event in pri-
mary ALL [27,34], has been shown to be present in pediatric 
cases with MLL alterations. Methylation of FHIT gene 
showed a similar pattern [23,24]. Even though the above 
results need to be confirmed in other larger group of pa-
tients, they suggest that prognostic differences between the 
age groups could be related in part to different methylation 
patterns [35]. 
Several studies have focused on whether DNA methyl-
ation could be used as a marker of residual disease. One 
study of methylation profiles of five genes (ER, MDR1, p73, 
p15 and p16) in a group of patients before therapy and 
at the time of morphologic relapse showed that a gain of 
methylation may have a role in relapse/resistance mecha-
nisms in adult ALL, which can suggest a potential role of 
DNA methylation profile in implicating relapse and resist-
ance [4]. Another study conducted in adult Ph chromo-
some-negative ALL patients showed that 28% of patients 
had detectable residual methylation at remission, and the 
presence of residual p73 methylation was associated with 
a significant shorter duration of first CR and OS [19]. As 
many authors suggested the different characteristics of 
methylation between adult and pediatric patients, methyl-
ation pattern at remission status in childhood ALL can differ 
from those of adults. 
In this study, we have analyzed the methylation patterns 
of CDH1, p16 and DAPK genes at the time of initial diag-
nosis and at the time of CR in 43 childhood ALL. Aberrant 
DNA methylation was most frequently observed in CDH1 
gene (60.4%), while it was rare in p16 and DPAK gene had 
several such cases. As Gutierrez et al. [18] reported high 
frequency (72%) of CDH1 methylation in childhood ALL, 
this data supports this result. Age was the only factor which 
showed statistically significant association with the presence 
of DNA methylation of the studied genes (P=0.03). Even 
though patients under age of two years are known to have 
poor prognosis, a majority of patients did not show any 
methylation. Most patients over 10 years had methylation. 
This result can be supported by the concept that methyl-
ation increases with aging [36], and may suggest a role of 
more significant mechanism in leukemogenesis other than 
epigenetic mechanism in those young children under age 
of two. However, since this study included only a very 
small number of genes among many different cancer-re-
lated genes in limited number of patient, further survey is 
definitely required. 
Most significant result of this study is that all patients 
who had DNA methylation at initial presentation showed 
clear absence of methylation at CR after induction chemo-
therapy. Unlike the results of the analysis of residual meth-
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ylation in Ph-negative adult patients, none of the childhood 
ALL patients at clinical remission showed residual or newly 
developed methylation of the studied genes. Since there 
was no patient with residual methylation at clinical re-
mission, we were unable to evaluate the correlation of clin-
icopathological factors with methylation status at CR in this 
study. It also was difficult to identify if residual methylation 
status could predict relapse or poor prognosis. Several limi-
tations are included in this study. First, the selection of 
genes for this study might not represent methylation pro-
files in childhood ALL. Since there are no representative 
genes known to carry the most relevant epigenetic role in 
childhood ALL, we selected the three genes based on prior 
results from other studies as we mentioned before. By in-
cluding more genes which have a potential epigenetic role 
in childhood ALL, we might have more obvious results of 
methylation status at CR. The second problem is the limi-
tation in detecting methylation. This study was conducted 
only with MSP which is limited to qualitative analysis. Since 
we did not undergo quantitative studies, the analysis ac-
cording to the level of methylation was unavailable. We be-
lieve that further qualitative analysis is certainly needed. 
Next, the follow up period was relatively short to evaluate 
the significance of methylation on survival outcome. Further 
studies of a larger patient number with the more selected 
genes and a long term follow up will give us better under-
standing of the driving mechanisms and also therapeutic in-
terventions for childhood ALL at diagnosis, treatment and 
relapse. 
In conclusion, we have analyzed methylation status of 
CDH1, p16 and DAPK genes in childhood ALL at the time 
of initial diagnosis and at CR using MSP method. Methylation 
of CDH1 was frequently detected, showing significant asso-
ciation with age. Since all of the DNA methylation pre-
sented at the time of diagnosis revealed total unmethylation 
at CR and all healthy individuals showed complete unme-
thylation. Further studies with larger populations and more 
relevant genes should be conducted in methods that in-
clude quantitative ones. 
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